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Abstract
Cannabis is the most cultivated and abused illicit drug worldwide. Paradoxically to the antiemetic properties attributed 
to cannabis, a relatively new cannabinoid hyperemesis syndrome (CHS) started to be recognized and is characterized by 
cyclic vomiting that are interspaced by asymptomatic phases. 
We present a case of a 36 ‑year ‑old woman who repeatedly presented to the emergency room with cyclic vomiting that 
alleviated with hot showers. She was a long ‑term cannabis user and the diagnosis was only established several years later 
after the onset of symptoms. The diagnostic work up was unremarkable, and the only effective treatment was cannabis 
cessation. Hot bathing behavior is a key characteristic of this syndrome. 
CHS is a new clinical condition that should be considered in a setting of recurrent and intractable vomiting in patients 
with a history of cannabis use. 
Resumo
O canábis é a substância ilícita mais cultivada e consumida em todo o mundo. Paradoxalmente às propriedades antieméti‑
cas atribuídas ao canábis, a síndrome de hiperemese por canabinóides (SHC) começou a ser reconhecido e é caracterizado 
por episódios de vómitos cíclicos espaçados por períodos assintomáticos. 
Apresentamos o caso de uma mulher de 36 anos com múltiplos recursos ao serviço de urgência por vómitos persistentes 
que aliviavam com banhos quentes. Tinha história de consumos de canabinóides desde longa data e o diagnóstico de SHC 
só foi estabelecido após vários anos. O estudo complementar não revelou alterações e o único tratamento eficaz foi a 
cessação dos consumos. O recurso a banhos quentes é uma característica central deste quadro clínico.
A SHC é uma entidade clínica que deve ser considerada em contexto de vómitos recorrentes difíceis de tratar em doentes 
com história de consumos de canábis. 
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INTRODUCTION
According to the World Health Organization, Cannabis 
is the most abused illicit drug, being consumed by over 
147 million people worldwide. Its use has been growing 
especially in North America, western Europe and Austra‑
lia.1 In fact, only in European Union (EU) around 91.2 mil‑
lion adults with an age span between 15 and 64 years are 
estimated to have used cannabinoids at least once during 
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their lives. Regarding the frequency of its consumption, 
1% of adults in EU consume cannabis on a daily or near‑
‑daily basis, being the prevalence significantly higher in 
young people aged below 35 years. Aligned with this data, 
the cases related to cannabinoids use disorder entering to 
treatment for the first time increased 76% between 2006 
and 2017.2,3 Portugal figures follow this trend with canna‑
bis ranking first as the most used psychotropic substance.4 
Cannabis has been credited with some medical properties 
showing efficacy in reducing nausea and vomiting during 
chemotherapy treatment, enhancing appetite and weight 
gain and improving chronic pain.5,6 Paradoxically to the 
antiemetic properties attributed to cannabis, a syndrome 
characterized by cyclic vomiting episodes in long term 
cannabis users started to be recognized. The first report 
describing cannabinoid yperemesis syndrome was pub‑
lished in 2004 by Allen et al, giving account of a series of 
patients observed for persistent vomiting alleviated by hot 
showering, a core behavior exhibited by the patients in the 
acute phase of the illness.7 
However, most of the people presenting this syndrome 
remain without a diagnosis for several years and it is 
therefore extremely important that clinicians are aware of 
the existence of this condition. Given the growing use of 
cannabis, the purpose of this report is to provide a better 
understanding of CHS and draw readers attention to its 
recognition.
CASE REPORT
We report the case of a 36 ‑year ‑old woman who was sent 
to the psychiatry outpatient clinic after recurring multiples 
times to the Emergency Room (ER) with gastrointestinal 
complains. 
For the last 14 years, the patient kept coming to the hospi‑
tal emergency department presenting with persisting vom‑
iting associated with abdominal pain and nausea. There 
were no complains of chills, fever, diarrhea, palpitations, 
thoracic pain, loss of conscience and genitourinary tract 
symptoms. She had a history of cannabis consumption 
since she was 16 years old and used the substance almost 
on a daily basis. She denied using other illicit drugs.
She admitted spending a significant amount of time taking 
hot water showers at home, stating that this behavior was 
the only way to mitigate the symptoms. In fact, even dur‑
ing the observations in the ER, she was frequently found 
in the bathroom showering. The patient described to have 
experienced numerous similar episodes before in an inter‑
mittently fashion. Each episode would start 7 days prior 
seeking medical attention.
Regarding her past medical history, she had no other chron‑
ic medical conditions and allergies. She had been admitted 
twice into the psychiatry ward after two of these episodes 
due to psychomotor agitation and anxiety causing familiar 
distress. She was diagnosed with dysfunctional personality 
traits and medicated with venlafaxine and quetiapine with 
poor therapeutic adhesion. 
Physical examination was unremarkable with the ex‑
ception of the mild epigastric tenderness the patient 
complained during abdominal palpation and mild dehy‑
dration. Often, the laboratory values revealed electrolyte 
imbalances such as hypokalemia and positive urine testing 
for cannabinoids. 
Reviewing the previous workup records, the patient was 
submitted to an extensive diagnosis investigation inclu‑
ding imagiology and laboratory exams. Abdominal radio‑
graphy and ultrasonography were normal. Other analytic 
results extending to complete blood count, liver function, 
amylase, lipase, thyroid hormones, viral serologies and 
urinalysis were unremarkable. 
During these episodes the patient remained under observa‑
tion in the ER. Supportive treatment with fluid therapy and 
antiemetic agents like metoclopramide and ondansetron 
were given in the acute phase and abstinence of cannabis 
consumption was advised.  
Cannabinoid hyperemesis syndrome was only pointed out 
as the diagnosis for this patient 6 years after the first time 
she went to ER with this clinical picture.  
DISCUSSION
Cannabis is a complex plant that contains over 400 che‑
mical compounds, including at least 144 unique products 
known as cannabinoids.8,9 One of the major substances 
produced is ∆9 ‑tetrahydrocannabinol (THC), which is 
responsible for the psychoactive effects of feeling high 
pursued by its users, but also for other disagreeable effects 
like psychosis and impairment of cognitive performance. 
THC exerts its effects by activating the endocannabinoid 
system that on its turn has two receptors known as CB1 
and CB2. CB1 is located in the central and peripheral 
nervous system and the stimulation of the latter causes va‑
sodilation and decrease gastric emptiness.10 CB2 receptors 
can be found in immune cells and are involved in immuno‑
modulation by inhibiting inflammation, visceral pain, and 
intestinal motility.11
THC demonstrated to have antiemetic properties medi‑
ated by activation of CB1 receptors in myenteric plexus 
and dorsal ‑vagal complex in the medulla.12 Nevertheless, 
CHB brings evidence for its paradoxical emetic effects, 
leading to the elaboration of some explicative hypothesis 
over the years. One of them states that as cannabis is a 
very lipophilic substance, it accumulates in fat tissue for 
long periods. During times of stress or food deprivation, 
lipolysis release THC which produces a reintoxification 
effect that may contribute to CHB in sensitive subjects.13 
Since just a small percentage of long term cannabis users 
develop CHS, genetic polymorphisms in the cytochrome 
P450 enzymes might be responsible for the higher rate of 
emetic metabolites in these individuals.11 
Alongside with THC, other two non ‑psychotropic can‑
nabinoids present in cannabis may contribute for the de‑
velopment of CHS. They are cannabidiol (CBD) that in 
high doses enhance vomiting and cannabigerol (CBG) 
that antagonize CB1 and 5 ‑HT1A receptors contributing 
to emesis.11 
Cannabinoids also showed to influence gastrointestinal 
and colonic dysmotility and THC exerts an inhibitory 
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action on gastric emptying through inhibition of intrinsic 
cholinergic mechanisms in peripheral myenteric system. 
This peripheral action can override the central actions of 
THC and producing vomiting.12,14  
The stimulation of CB1 receptors in the hypothalamus 
and pituitary gland helps to modulate the hypothalamic‑
‑pituitary axe. THC produces a hypothermic effect that 
is amplified by the action of CBD that upregulate CB1 
receptors in the hypothalamus.11 These mechanisms may 
contribute to understand why patients with CHS show the 
compulsive bathing behavior. 
Concerning the diagnosis, Sorensen et al made a sys‑
tematic review and identified the major characteristics of 
CHS as severe cyclic vomiting (100%), abdominal pain 
(85.1%), weekly use of cannabis (97.4%), consumption of 
cannabis for over a year (74.8%), resolution of the symp‑
toms after cannabis cessation (96.8%), temporary symp‑
tomatic relieve with compulsive hot showers (92.3%) and 
age less than 50 at time of evaluation (100%) . 92% of the 
patients evaluated met at least three of the latter criteria. 
The diagnosis of CHS is made with a mean delay of 4.1 
years after the beginning of the symptoms.15  
The only treatment that showed efficacy is cannabis ces‑
sation. In the acute phase, supportive treatment including 
intravenous fluids should be provided if there is volume 
depletion and renal failure or electrolytic imbalances. Ap‑
plication of topic capsaicin on the abdomen may relieve 
the symptoms, and this effect is exerted by activation of 
TRVP ‑1 receptors producing a heat sensation. Haloperidol 
was used successfully in some reports. Opioids are not 
recommended as they might aggravated the nausea.11,16 
The acute phase usually resolves in 48 hours, but relapse 
is likely to occur if the patient resumes cannabis use.11
The case presented here is paradigmatic of the delay until 
the recognition CHS in a long ‑term cannabis user with 
multiples recurrences to ER with cyclic vomiting. Moreo‑
ver, the patient went to extensive non conclusive diagnos‑
tic workups, showing that CHS is still underdiagnosed.
CONCLUSION
Since the use of cannabis is growing and new medical 
indications are being considered it is important to pay at‑
tention to the paradoxical effects of cannabis and study its 
underlying pathophysiology.
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